Paul G. Richardson
Led the DETERMINATION trial and many of the myeloma drug approvals of the past two decades.
Principal investigator on pivotal trials of bortezomib, lenalidomide-based regimens and newer agents; led DETERMINATION, which tested delayed versus upfront transplant in the lenalidomide era.
| Title | Journal | Year |
|---|---|---|
| Triplet therapy, transplantation, and maintenance until progression in myeloma | New England Journal of Medicine | 2022 |
Pages like this
not linked directly; found by shared links- PersonKenneth C. Anderson
Shares Bortezomib, Lenalidomide, Dana-Farber Brigham Cancer Center, Multiple myeloma.
- TrialCEPHEUS
Shares Bortezomib, Lenalidomide, Multiple myeloma.
- TrialIMROZ
Shares Bortezomib, Lenalidomide, Multiple myeloma.
- TrialPERSEUS
Shares Bortezomib, Lenalidomide, Autologous stem cell transplant (high-dose therapy), Multiple myeloma.
- TrialDREAMM-7
Shares Bortezomib, Multiple myeloma.
- PersonBenjamin L. Ebert
Shares Lenalidomide, Dana-Farber Brigham Cancer Center, Multiple myeloma.
- Key paperPERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma
Shares Bortezomib, Lenalidomide, Autologous stem cell transplant (high-dose therapy), Multiple myeloma.
- ProductIberdomide
Shares Lenalidomide, Multiple myeloma.